Menactra Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Meningococcal (groups A, C, Y & W-135) polysaccharide diphtheria toxoid conjugate vaccine

Indications/Uses

Active immunization of individuals 9 mth to 55 yr for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y & W-135.

Dosage/Direction for Use

IM 0.5 mL as single dose preferably in the anterolateral thigh or deltoid region. Primary vaccination Individual 2-55 yr Single dose. Childn 9-23 mth 2-dose series at least 3 mth apart. Booster vaccination Individual 15-55 yr at continued risk for meningococcal disease Single booster dose, if at least 4 yr have elapsed since the prior dose.

Contraindications

Hypersensitivity after previous dose of meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM₁₉₇-containing vaccine. Postpone vaccination in case of moderate or severe febrile or acute disease.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.

Regulatory Classification

POM

Presentation/Packing

Form

Menactra vaccine (inj) 0.5 mL

Packing/Price

1's

Menactra

vaccine, meningococcal

Manufacturer:

sanofi pasteur